Loading...

Trevor Angell

TitleAssistant Professor of Clinical Medicine
InstitutionUniversity of Southern California
DepartmentMedicine
AddressBMT B11
Off Campus
Los Angeles CA 90089-9113
Phone+1 323 442 6179
vCardDownload vCard
    Other Positions
    TitleAssociate Medical Director of Thyroid Center


    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Cherella CE, Feldman HA, Hollowell M, Richman DM, Cibas ES, Smith JR, Angell T, Wang Z, Alexander EK, Wassner AJ. Natural History and Outcomes of Cytologically Benign Thyroid Nodules in Children. J Clin Endocrinol Metab. 2018 Jul 02. PMID: 29982665.
      View in: PubMed
    2. Patel KN, Angell T, Babiarz J, Barth NM, Blevins T, Duh QY, Ghossein RA, Harrell RM, Huang J, Kennedy GC, Kim SY, Kloos RT, LiVolsi VA, Randolph GW, Sadow PM, Shanik MH, Sosa JA, Traweek ST, Walsh PS, Whitney D, Yeh MW, Ladenson PW. Performance of a Genomic Sequencing Classifier for the Preoperative Diagnosis of Cytologically Indeterminate Thyroid Nodules. JAMA Surg. 2018 May 23. PMID: 29799911.
      View in: PubMed
    3. Angell T, Van Benschoten O, Cohen DA, Haas AV, Alexander EK, Marqusee E. POSITIVE THYROTROPIN RECEPTOR ANTIBODIES IN PATIENTS WITH TRANSIENT THYROTOXICOSIS. Endocr Pract. 2018 Apr 06. PMID: 29624097.
      View in: PubMed
    4. Wang Z, Vyas CM, Van Benschoten O, Nehs MA, Moore FD, Marqusee E, Krane JF, Kim MI, Heller HT, Gawande AA, Frates MC, Doubilet PM, Doherty GM, Cho NL, Cibas ES, Benson CB, Barletta JA, Zavacki AM, Larsen PR, Alexander EK, Angell T. Quantitative Analysis of the Benefits and Risk of Thyroid Nodule Evaluation in Patients =70 Years Old. Thyroid. 2018 Apr; 28(4):465-471. PMID: 29608439.
      View in: PubMed
    5. Lechner MG, Vyas CM, Hamnvik OR, Alexander EK, Larsen PR, Choueiri TK, Angell T. Risk Factors for New Hypothyroidism During Tyrosine Kinase Inhibitor Therapy in Advanced Nonthyroidal Cancer Patients. Thyroid. 2018 Apr; 28(4):437-444. PMID: 29652599.
      View in: PubMed
    6. Lechner MG, Vyas CM, Hamnvik OR, Alexander EK, Larsen PR, Choueiri TK, Angell T. Hypothyroidism During Tyrosine Kinase Inhibitor Therapy Is Associated with Longer Survival in Patients with Advanced Nonthyroidal Cancers. Thyroid. 2018 Apr; 28(4):445-453. PMID: 29652597.
      View in: PubMed
    7. Angell T, Vyas CM, Barletta JA, Cibas ES, Cho NL, Doherty GM, Gawande AA, Howitt BE, Krane JF, Marqusee E, Strickland KC, Alexander EK, Moore FD, Nehs MA. Reasons Associated with Total Thyroidectomy as Initial Surgical Management of an Indeterminate Thyroid Nodule. Ann Surg Oncol. 2018 May; 25(5):1410-1417. PMID: 29520656.
      View in: PubMed
    8. Strickland KC, Eszlinger M, Paschke R, Angell T, Alexander EK, Marqusee E, Nehs MA, Jo VY, Lowe A, Vivero M, Hollowell M, Qian X, Wieczorek T, French CA, Teot LA, Cibas ES, Lindeman NI, Krane JF, Barletta JA. Molecular Testing of Nodules with a Suspicious or Malignant Cytologic Diagnosis in the Setting of Non-Invasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features (NIFTP). Endocr Pathol. 2018 Mar; 29(1):68-74. PMID: 29396809.
      View in: PubMed
    9. Angell T, Vyas CM, Medici M, Wang Z, Barletta JA, Benson CB, Cibas ES, Cho NL, Doherty GM, Doubilet PM, Frates MC, Gawande AA, Heller HT, Kim MI, Krane JF, Marqusee E, Moore FD, Nehs MA, Zavacki AM, Larsen PR, Alexander EK. Differential Growth Rates of Benign vs. Malignant Thyroid Nodules. J Clin Endocrinol Metab. 2017 Dec 01; 102(12):4642-4647. PMID: 29040691.
      View in: PubMed
    10. Angell T, Min L, Wieczorek TJ, Hodi FS. Unique Cytologic Features of Thyroiditis Caused by Immune Checkpoint Inhibitor Therapy for Malignant Melanoma. Genes Dis. 2018 Mar; 5(1):46-48. PMID: 29619406.
      View in: PubMed
    11. Angell T. RAS-positive thyroid nodules. Curr Opin Endocrinol Diabetes Obes. 2017 Oct; 24(5):372-376. PMID: 28639967.
      View in: PubMed
    12. Mito JK, Alexander EK, Angell T, Barletta JA, Nehs MA, Cibas ES, Krane JF. A modified reporting approach for thyroid FNA in the NIFTP era: A 1-year institutional experience. Cancer Cytopathol. 2017 Nov; 125(11):854-864. PMID: 28902465.
      View in: PubMed
    13. Wong KS, Strickland KC, Angell T, Nehs MA, Alexander EK, Cibas ES, Krane JF, Howitt BE, Barletta JA. The Flip Side of NIFTP: an Increase in Rates of Unfavorable Histologic Parameters in the Remainder of Papillary Thyroid Carcinomas. Endocr Pathol. 2017 Jun; 28(2):171-176. PMID: 28271380.
      View in: PubMed
    14. Paulson VA, Shivdasani P, Angell T, Cibas ES, Krane JF, Lindeman NI, Alexander EK, Barletta JA. Noninvasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features Accounts for More Than Half of "Carcinomas" Harboring RAS Mutations. Thyroid. 2017 04; 27(4):506-511. PMID: 28114855.
      View in: PubMed
    15. Baca SC, Wong KS, Strickland KC, Heller HT, Kim MI, Barletta JA, Cibas ES, Krane JF, Marqusee E, Angell T. Qualifiers of atypia in the cytologic diagnosis of thyroid nodules are associated with different Afirma gene expression classifier results and clinical outcomes. Cancer Cytopathol. 2017 05; 125(5):313-322. PMID: 28152275.
      View in: PubMed
    16. Kakarmath S, Heller HT, Alexander CA, Cibas ES, Krane JF, Barletta JA, Lindeman NI, Frates MC, Benson CB, Gawande AA, Cho NL, Nehs M, Moore FD, Marqusee E, Kim MI, Larsen PR, Kwong N, Angell T, Alexander EK. Clinical, Sonographic, and Pathological Characteristics of RAS-Positive Versus BRAF-Positive Thyroid Carcinoma. J Clin Endocrinol Metab. 2016 12; 101(12):4938-4944. PMID: 27689252.
      View in: PubMed
    17. Wong KS, Angell T, Strickland KC, Alexander EK, Cibas ES, Krane JF, Barletta JA. Noninvasive Follicular Variant of Papillary Thyroid Carcinoma and the Afirma Gene-Expression Classifier. Thyroid. 2016 07; 26(7):911-5. PMID: 27219469.
      View in: PubMed
    18. Jang JK, Khawli LA, Canter DC, Hu P, Zhu TH, Wu BW, Angell T, Li Z, Epstein AL. Systemic delivery of chTNT-3/CpG immunoconjugates for immunotherapy in murine solid tumor models. Cancer Immunol Immunother. 2016 May; 65(5):511-23. PMID: 26960932; PMCID: PMC4841721 [Available on 05/01/17].
    19. Angell T, Lechner MG, Smith AM, Martin SE, Groshen SG, Maceri DR, Singer PA, Epstein AL. Circulating Myeloid-Derived Suppressor Cells Predict Differentiated Thyroid Cancer Diagnosis and Extent. Thyroid. 2016 Mar; 26(3):381-9. PMID: 26756227; PMCID: PMC4790214 [Available on 03/01/17].
    20. Medici M, Liu X, Kwong N, Angell T, Marqusee E, Kim MI, Alexander EK. Long- versus short-interval follow-up of cytologically benign thyroid nodules: a prospective cohort study. BMC Med. 2016 Jan 27; 14:11. PMID: 26817603; PMCID: PMC4730757.
    21. Minkovsky A, Lee MN, Dowlatshahi M, Angell T, Mahrokhian LS, Petrides AK, Melanson SE, Marqusee E, Woodmansee WW. HIGH-DOSE BIOTIN TREATMENT FOR SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS MAY INTERFERE WITH THYROID ASSAYS. AACE Clin Case Rep. 2016; 2(4):e370-e373. PMID: 27917400.
      View in: PubMed
    22. Liu X, Medici M, Kwong N, Angell T, Marqusee E, Kim MI, Larsen PR, Cho NL, Nehs MA, Ruan DT, Gawande A, Moore F, Barletta J, Krane JF, Cibas ES, Yang T, Alexander EK. Bethesda Categorization of Thyroid Nodule Cytology and Prediction of Thyroid Cancer Type and Prognosis. Thyroid. 2016 Feb; 26(2):256-61. PMID: 26563459; PMCID: PMC4754507 [Available on 02/01/17].
    23. Kwong N, Medici M, Angell T, Liu X, Marqusee E, Cibas ES, Krane JF, Barletta JA, Kim MI, Larsen PR, Alexander EK. The Influence of Patient Age on Thyroid Nodule Formation, Multinodularity, and Thyroid Cancer Risk. J Clin Endocrinol Metab. 2015 Dec; 100(12):4434-40. PMID: 26465395.
      View in: PubMed
    24. Angell T, Frates MC, Medici M, Liu X, Kwong N, Cibas ES, Kim MI, Marqusee E. Afirma Benign Thyroid Nodules Show Similar Growth to Cytologically Benign Nodules During Follow-Up. J Clin Endocrinol Metab. 2015 Nov; 100(11):E1477-83. PMID: 26353010; PMCID: PMC4702458 [Available on 11/01/16].
    25. Medici M, Kwong N, Angell T, Marqusee E, Kim MI, Frates MC, Benson CB, Cibas ES, Barletta JA, Krane JF, Ruan DT, Cho NL, Gawande AA, Moore FD, Alexander EK. The variable phenotype and low-risk nature of RAS-positive thyroid nodules. BMC Med. 2015 Aug 07; 13:184. PMID: 26253102; PMCID: PMC4528713.
    26. Angell T, Swaika A, Sood N, Goldfarb M, Siddiqi I, Ailawadhi S. Localized LECT2 amyloidosis of the adrenal gland with coexisting MGUS: a diagnostic challenge. Ann Hematol. 2015 Sep; 94(9):1603-4. PMID: 26048244.
      View in: PubMed
    27. Angell T, Lechner MG, Nguyen CT, Salvato VL, Nicoloff JT, LoPresti JS. Clinical features and hospital outcomes in thyroid storm: a retrospective cohort study. J Clin Endocrinol Metab. 2015 Feb; 100(2):451-9. PMID: 25343237.
      View in: PubMed
    28. Angell T, Lechner MG, Jang JK, LoPresti JS, Epstein AL. MHC class I loss is a frequent mechanism of immune escape in papillary thyroid cancer that is reversed by interferon and selumetinib treatment in vitro. Clin Cancer Res. 2014 Dec 01; 20(23):6034-44. PMID: 25294906; PMCID: PMC4252612.
    29. Angell T, Lechner MG, Jang JK, Correa AJ, LoPresti JS, Epstein AL. BRAF V600E in papillary thyroid carcinoma is associated with increased programmed death ligand 1 expression and suppressive immune cell infiltration. Thyroid. 2014 Sep; 24(9):1385-93. PMID: 24955518; PMCID: PMC4148060.
    30. Angell T, Spencer CA, Rubino BD, Nicoloff JT, LoPresti JS. In search of an unstimulated thyroglobulin baseline value in low-risk papillary thyroid carcinoma patients not receiving radioactive iodine ablation. Thyroid. 2014 Jul; 24(7):1127-33. PMID: 24697314.
      View in: PubMed
    31. Lechner MG, Karimi SS, Barry-Holson K, Angell T, Murphy KA, Church CH, Ohlfest JR, Hu P, Epstein AL. Immunogenicity of murine solid tumor models as a defining feature of in vivo behavior and response to immunotherapy. J Immunother. 2013 Nov-Dec; 36(9):477-89. PMID: 24145359; PMCID: PMC3910494.
    32. Lechner MG, Megiel C, Church CH, Angell T, Russell SM, Sevell RB, Jang JK, Brody GS, Epstein AL. Survival signals and targets for therapy in breast implant-associated ALK--anaplastic large cell lymphoma. Clin Cancer Res. 2012 Sep 01; 18(17):4549-59. PMID: 22791880.
      View in: PubMed